CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.

 

Begin main content

Reports

We found 17 result(s)

Brain Electrical Activity Mapping for Diagnosing Psychiatric Disorders: A Review of the Clinical Evidence

Last Updated: November 4, 2014
Result type: Reports
Product Line: Rapid Response
Research Type: Other Diagnostics

Report in Brief Context
Psychiatric disorders are thought to result from imbalances of certain neurotransmitters, or chemicals in the brain. For example, Alzheimer disease may be associated with a lack of acetylcholine, serotonin, and gamma-aminobutyric acid (GABA), while psychoses such as schizophrenia...

  • Project Number: RC0601-000

Aripiprazole (Abilify Maintena)

Last Updated: January 6, 2014
Result type: Reports
Product Line: Reimbursement Review
Generic Name: Aripiprazole
Indications: Schizophrenia

  • Brand Name: Abilify Maintena
  • Manufacturer: Otsuka Canada Pharmaceutical Inc. & Lundbeck Canada Inc.
  • Project Number: SR0366-000
  • Project Status: Complete
  • Submission Type: Initial

Repetitive Transcranial Magnetic Stimulation for Specific Patient Populations: Clinical and Cost-Effectiveness and Safety

Last Updated: January 15, 2013
Result type: Reports
Product Line: Rapid Response
Research Type: Devices and Systems

Report in Brief Context
Deep brain stimulation uses implanted electrodes in the brain to deliver electrical impulses, and is used to treat movement disorders and obsessive compulsive disorder - usually when medication is not working to control symptoms. Another type of brain stimulation called repetitiv...

  • Project Number: RC0417-000

Combination and High-Dose Atypical Antipsychotic Therapy in Patients with Schizophrenia: Systematic Review

Last Updated: August 23, 2012
Result type: Reports

Adapted from A Systematic Review of Combination and High-Dose Atypical Antipsychotic Therapy in Patients with Schizophrenia [CADTH Optimal Use Report; Volume 1, Issue 1B]. Ottawa: Canadian Agency for Drugs and Technologies in Health; 2011. For more information on this project, visit https://www.cadth.ca/atypical-antipsychotics-schizophrenia-com...

Atypical Antipsychotics for Schizophrenia: Combination Therapy and High Doses

Last Updated: December 15, 2011
Result type: Reports
Product Line: Optimal Use

The Canadian Agency for Drugs and Technologies in Health (CADTH) has undertaken an optimal use project to assess the clinical and economic impact of using atypical antipsychotic combination therapy, as well as high-dosing treatment strategies, in adolescents and adults with schizophrenia. The current project has several key components: Appra...

  • Project Number: HO503-000